Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer |
Huang, Xin-En
(Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Yan, Xiao-Chun (Department of Medical Oncology, Huai An Cancer Hospital) Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Ji, Zhu-Qing (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Li, Li (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Liu, Meng-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Qian, Ting (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Shen, Hui-Ling (Zhenjiang First People's Hospital) Gu, Han-Gang (Jisngsu University Hospital) Liu, Yong (Xu Zhou Central Hospital) Gu, Ming (Yan Cheng Third Hospital) Deng, Li-Chun (Jiang Yin People's Hospital) |
1 | Govindarajan R (2002). Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Huntingt), 16, 23-6. |
2 | Haslett PA, Corral LG, Albert M, et al (1998). . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med, 187, 1885-1892. DOI |
3 | Jemal A, Bray F, CenterMMet al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
4 | Jin SH, Kim TI, Han DS, et al (2002). Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann NY Acad Sci, 973, 414-8. DOI |
5 | Keifer JA, Guttridge DC, Ashburner BP, et al (2001). Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem, 276, 22382-7. DOI |
6 | Lago LD, Richter MF, Cancela AI, et al ( 2003). Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs, 21, 359-66. DOI |
7 | Nogue M, Segui MA, Batiste E et al (1996). Phase II study of oral Tegafur (TF) and low-dose oral leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol, 15, 200 (Abstr). |
8 | Plate KH, Breier G, Weich HA, et al (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-8. DOI |
9 | Prat A, Casado E, Cortes J (2007). New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol, 13, 5857-66. DOI |
10 | Rajkumar SV, Witzig TE (2000). A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev, 26, 351-62. DOI |
11 | Shweiki D, Itin A, Soffer D, et al (1992 ). Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature, 359, 843-5. DOI |
12 | Veikkola T, Karkkainen M, Claesson-Welsh L, et al (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res, 60, 203-12, |
13 | Yang X, Hu Z, Chan SY, et al (2005). Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. J Chromatogr B Anal Technol Biomed Life Sci, 821, 221-8. DOI |
14 | Bartlett JB, Dredge K, Dalgleish AG et al (2004). The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer, 4, 314-22. DOI |
15 | Battegay EJ (1995). Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med, 73, 333-46. |
16 | Carmeliet P, Ferreira V, Breier G, et al (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, 435-9. DOI |
17 | Findlay M, Van Cutsem E, KochaW, et al (1997). A randomized phase II study of capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol, 16, 227a (Abstr). |
18 | D'Amato RJ, Loughnan MS, Flynn E, et al (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 91, 4082-5. DOI |
19 | Ferlay J, Shin HR, Bray F, et al ( 2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI |
20 | Ferrara N (1999). Molecular and biological properties of vascular endothelial growth factor. J Mol Med, 77, 527-43. DOI |
21 | Fine HA, Wen PY, Maher EA, et al (2003). Phase II trial of thalidomide and carmustine for patients with recurrent highgrade gliomas. J Clin Oncol, 21, 2299-304. DOI |
22 | Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31. DOI |
23 | Folkman J (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 333, 1757-63. DOI |
24 | Fujita J, Mestre JR, Zeldis JB, et al (2001). Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res, 7, 3349-55. |
25 | Geitz H, Handt S, Zwingenberger K (1996). Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-21. DOI |
26 | Gerber HP, Hillan KJ, Ryan AM, et al (1999). VEGF is required for growth and survival in neonatal mice. Development, 126, 1149-59. |